The evolving role of Alemtuzumab in management of patients with CLL

S. Faderl, S. Coutré, J. C. Byrd, C. Dearden, A. Denes, M. J.S. Dyer, S. A. Gregory, J. G. Gribben, P. Hillmen, M. Keating, S. Rosen, P. Venugopal, K. Rai

Research output: Contribution to journalArticlepeer-review

30 Scopus citations


New insights into prognostic markers and the pathophysiology of chronic lymphocytic leukemia (CLL) are beginning to change the concept of CLL treatment. Alemtuzumab has evolved as a potent and effective therapeutic option for patients with CLL. Specifically, alemtuzumab has demonstrated substantial efficacy in fludarabine-refractory patients and has shown impressive responses when administered subcutaneously in first-line therapy. A group of experts gathered to discuss new data related to the use of alemtuzumab in CLL and to assess its place in the rapidly changing approach to treating patients with this disease. The main goals of this program were to update the management guidelines that were previously developed for alemtuzumab-treated patients and to provide community oncologists with guidance on the most effective way to integrate alemtuzumab into a CLL treatment plan.

Original languageEnglish (US)
Pages (from-to)2147-2152
Number of pages6
Issue number12
StatePublished - Dec 2005
Externally publishedYes


  • Alemtuzumab
  • CLL therapy
  • Minimal residual disease
  • Patient management
  • Treatment guidelines

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'The evolving role of Alemtuzumab in management of patients with CLL'. Together they form a unique fingerprint.

Cite this